Skip to content

The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease

The Combination of Ophthalmologic Tests and EEG Imaging as a New Biomarker for Alzheimer's Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04277767
Enrollment
60
Registered
2020-02-20
Start date
2022-09-01
Completion date
2023-07-01
Last updated
2021-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

AD EEG OCT biomarker

Brief summary

Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the disease. Meantime, EEG resting state has also demonstrated significant change in patients with AD in neuroscience research area. Thus, the combination of these sensitive biomarkers would lead to a potential new biomarker for detection of AD, which has higher specificity and sensitivity.

Interventions

DIAGNOSTIC_TESTobservational

No intervention

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of Alzheimer's Disease

Exclusion criteria

* neurologic disorders * psychiatric disorders

Design outcomes

Primary

MeasureTime frameDescription
OCT retinal and choroidal thickness2 daysretinal structural anatomy
Retinal Photography vascular caliber2 daysuse Retinal Photography to detect vascular caliber
functional connection strength in the brain network7 daysrecord resting-state EEG, use graph theory to calculate the functional connection strength

Countries

China

Contacts

Primary ContactJin Yuan, phD
yuanjincornea@126.com13825141659
Backup ContactLi Gu, phD
guli7@mail2.sysu.edu.cn+8615889937313

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026